As many know, being first to market has always been a top goal for companies in the biopharmaceutical industry. Increased competition, among other factors, further emphasizes this need. Yet, moving too quickly can open your drug development program to other risks, making it critical to achieve the optimal program profile for a seamless transition from gene to IND and beyond.
Lonza Pharma & Biotech’s Abdelaziz Toumi, PhD, Head of Customer Solutions, Ibex ® Design & Develop, and Atul Mohindra, PhD, Head of Biomanufacturing, Research & Development, recently presented the webinar, Gene to IND in 12 Months Without Increased Risk. In it, Drs. Toumi and Mohindra discussed how Lonza’s Ibex® Design solution can help small biotech companies navigate through early phase uncertainty by de-risking and accelerating the path toward commercialization. The following Q&A session was held after this webinar, where Drs. Toumi and Mohindra were able to address attendee questions about the program.